Gonnissen - Hollanders SRL
Gonnissen - Hollanders reported total assets of 75,759 € at the end of the 2025 financial year (annual accounts filed with the NBB on 14 Jul 2026).
The score of Gonnissen - Hollanders shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +7766 % Total assets +7603 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Gonnissen - Hollanders's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 14 Jul 2026
- Year ended 31 Dec 2024filed on 11 Jul 2025
- Year ended 31 Dec 2023filed on 12 Jul 2024
- Year ended 31 Dec 2022filed on 31 Jul 2023
- Year ended 31 Dec 2021filed on 29 Jul 2022
Gonnissen - Hollanders's financial analysis
- Solvency85.3%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Gonnissen - Hollanders
Gonnissen - Hollanders's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0822.504.174
- VAT number
- BE0822504174
- Peppol
- Registered · 0208:0822504174 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 14 Jan 2010
- Registered office
- 2180 Antwerp
- Latest accounts
- 2025 · filed on 14 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Gonnissen - Hollanders (SRL) has been based in Antwerp since 2010, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 22,529 € and equity of 64,590 €; its revenue is not published. Its solvency stands at 85.3%, above the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Gonnissen - Hollanders
Companies in the same business, of comparable size and area, outside its group.
- DD Pharma Retail sale of pharmaceutical products Leuven · balance sheet 75,776 €
- Pharmacie Stalingrad Retail sale of pharmaceutical products Brussels · balance sheet 75,864 €
- Farma Dewolf Retail sale of pharmaceutical products Herent · balance sheet 75,439 €
- ESPharma Retail sale of pharmaceutical products Anderlecht · balance sheet 74,825 €
- Arucarea Retail sale of pharmaceutical products Oud-Turnhout · balance sheet 73,983 €
- Sagenex Retail sale of pharmaceutical products Namur · balance sheet 73,820 €
- Sirrah Retail sale of pharmaceutical products Tournai · balance sheet 84,897 €
- Arkophar Retail sale of pharmaceutical products Zutendaal · balance sheet 73,718 €
Frequently asked questions about Gonnissen - Hollanders
What is the revenue of Gonnissen - Hollanders?
Gonnissen - Hollanders files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Gonnissen - Hollanders?
In Belgium, the VAT number is the company number prefixed with BE: BE0822504174 for Gonnissen - Hollanders, if the company is VAT-registered. Its company number (CBE) is 0822.504.174.
Where is the registered office of Gonnissen - Hollanders?
According to the CBE register, the registered office of Gonnissen - Hollanders is in 2180 Antwerp.
What is the equity of Gonnissen - Hollanders?
At the close of the 2025 financial year, the equity of Gonnissen - Hollanders amounts to 64,590 €, a solvency of 85.3% of total assets.
Who manages Gonnissen - Hollanders?
The register lists 2 active mandates at Gonnissen - Hollanders. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Gonnissen - Hollanders
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →